Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
Completed · Phase 1
Conditions studied: Hepatic Impairment, Healthy
In brief
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
Key facts
- Study ID
- NCT05765344
- Run by
- Gilead Sciences
- People needed
- 74
- Starts
- 2023-03-15
- Expected to finish
- 2025-01-13
- Last updated by the study team
- 2026-01-26
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orange County Research Center — Lake Forest, California, United States
- Clinical Pharmacology of Miami, LLC — Miami, Florida, United States
- University of Miami — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- Texas Liver Institute — San Antonio, Texas, United States
- Pinnacle Clinical Research LLC — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.